年轻男性筛查中是否需要早期检出GG2前列腺癌?PROBASE试验结果
基于PROBASE筛查试验中45岁起始、PSA 1.5-2.99 ng/ml的中危组,分析前两轮 biennial 筛查中因确认PSA≥3 ng/ml而进行的159例活检。活检阳性率37%,其中78%(46/59)为GG1或GG2疾病;仅0.8%(13/1661)中危男性为GG3-5前列腺癌,若改为5年间隔筛查其诊断延迟1-3年。结果提示中危男性筛查间隔可从2年延长至5年,减少不必要检测和过度诊断。
要点
- 中危男性活检阳性者中78%为GG1或GG2,仅0.8%为GG3-5。
- 5年间隔筛查可使GG3-5诊断延迟1-3年。
- 中危男性筛查间隔或可延长至5年,减少过度诊断。
核心结论
- 45岁中危男性前列腺癌筛查间隔可从2年延长至5年,类似低危男性。
研究设计与样本
- PROBASE筛查试验中PSA 1.5-2.99 ng/ml中危组分析,评估159例因PSA≥3 ng/ml进行的活检。
主要发现
- 活检阳性率37%,其中78%(46/59)为GG1或GG2疾病。
- 仅0.8%(13/1661)中危男性为GG3-5前列腺癌,5年间隔筛查延迟诊断1-3年。
关键数值与推荐
- 中危定义为PSA 1.5-2.99 ng/ml,活检指征为确认PSA≥3 ng/ml。
临床怎么用
- 对45岁中危男性可考虑将筛查间隔延长至5年,减少不必要检测和过度诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In general, low-risk and favorable intermediate-risk prostate cancers (PCs; International Society of Urological Pathology grade group [GG] 1 and GG 2) are slow-growing cancers with low metastatic potential. Active surveillance is recommended for GG 1 PC and can be recommended for GG 2 PC in the absence of adverse pathological parameters. Therefore, the question arises as to when low-grade PC should be detected in a screening setting. We conducted an analysis of the group with intermediate prostate-specific antigen (PSA) risk (1.5-2.99 ng/ml) from the PROBASE screening trial for young men (starting age 45 yr) and evaluated 159 biopsies performed for confirmed PSA ≥3 ng/ml in the first two biennial screening rounds. Of these biopsies, 37% were positive, with 78% (46/59) showing GG 1 or GG 2 disease. Only 0.8% of men with intermediate risk (13 of 1661 men screened) had GG 3-5 PC and would have experienced a delay in diagnosis of between 1 and 3 yr if screening were performed at 5-yr intervals. These results suggest that the screening interval could be extended from 2 yr to 5 yr for men aged 45 yr at intermediate risk, similar to the interval for men at low risk (PSA <1.5 ng/ml). This would reduce unnecessary testing and overdiagnosis in nearly 10% of the screening population aged 45 yr.
引用
- Albers P, Krilaviciute A, Seibold P, et al. Do We Need Early Detection of Grade Group 2 Prostate Cancer in a Screening Program for Young Men? Results from the PROBASE Screening Trial. Eur Urol Oncol. 2025. PMID: 40640052. doi:10.1016/j.euo.2025.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。